Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 20/20 | 0.86 |
| ▸ | TEC | P42680 | 1/20 | 0.79 |
| ▸ | TXK | P42681 | 1/20 | 0.79 |
| ▸ | BMX | P51813 | 1/20 | 0.79 |
| ▸ | ITK | Q08881 | 1/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10207710 | 0.93 | BTK (0.82) | BTKTECTXKBMXITK | |
| SCHEMBL1531597 | 0.93 | BTK (1.00) | BTKTECTXKBMXITK | |
| SCHEMBL10206526 | 0.93 | BTK (1.00) | BTKTECTXKBMXITK | |
| SCHEMBL10206310 | 0.93 | BTK (0.80) | BTKTECTXKBMXITK | |
| SCHEMBL10207707 | 0.92 | BTK (0.80) | BTKTECTXKBMXITK | |
| SCHEMBL1531460 | 0.91 | BTK (0.80) | BTKTECTXKBMXITK | |
| SCHEMBL10206539 | 0.91 | BTK (0.83) | BTKTECTXKBMXITK | |
| SCHEMBL1531491 | 0.91 | BTK (0.83) | BTKTECTXKBMXITK | |
| SCHEMBL1531482 | 0.90 | BTK (0.89) | BTKTECTXKBMXITK | |
| SCHEMBL10206518 | 0.89 | BTK (1.00) | BTKTECTXKBMXITK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9029359-B2 | Heteroaryl Btk inhibitors | BIOGEN IDEC MA, INC. (US) | 2015-05-12 | — | — | US | disclosed |
| US-9029359-B2 | Heteroaryl Btk inhibitors | BIOGEN IDEC MA, INC. (US) | 2015-05-12 | — | — | US | disclosed |
| EP-2485589-A1 | HETEROARYL BTK INHIBITORS | Biogen Idec MA Inc. (US) | 2012-08-15 | — | — | EP | disclosed |
| US-20120157442-A1 | HETEROARYL BTK INHIBITORS | SUNESIS PHARMACEUTICALS, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120157442-A1 | HETEROARYL BTK INHIBITORS | SUNESIS PHARMACEUTICALS, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| WO-2011029043-A1 | HETEROARYL BTK INHIBITORS | BIOGEN IDEC MA INC. (US) | 2011-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157442-A1 | HETEROARYL BTK INHIBITORS | BTK, LYN, SYK | BTK 1/4885TEC 7/4885TXK 339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.